Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 890 | 150 | 721 |
| Samples | 440 | 91 | 337 |
| Peptides | 346 | 61 | 283 |
Function
IPO5 · Importin 5
Nucleocytoplasmic transport, a signal- and energy-dependent process, takes place through nuclear pore complexes embedded in the nuclear envelope. The import of proteins containing a nuclear localization signal (NLS) requires the NLS import receptor, a heterodimer of importin alpha and beta subunits also known as karyopherins. Importin alpha binds the NLS-containing cargo in the cytoplasm and importin beta docks the complex at the cytoplasmic side of the nuclear pore complex. In the presence of nucleoside triphosphates and the small GTP binding protein Ran, the complex moves into the nuclear pore complex and the importin subunits dissociate. Importin alpha enters the nucleoplasm with its passenger protein and importin beta remains at the pore. Interactions between importin beta and the FG repeats of nucleoporins are essential in translocation through the pore complex. The protein encoded by this gene is a member of the importin beta family. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
5 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000261574 | O00410-3 | 414 | 320 |
| ENST00000490680 | O00410 | 404 | 311 |
| ENST00000651721 | O00410 | 56 | 54 |
| ENST00000631030 | A0A0D9SG25* | 15 | 14 |
| ENST00000460070 | E7EV12* | 1 | 1 |
Gene Properties
Recurrent Mutations
All 320 amino-acid changes on canonical ENST00000261574 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in IPO5 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in IPO5 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 5/40 12% | 0/0 0% |
| Oral Cavity Carcinoma | 4/54 7% | 0/0 0% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Endometrial Carcinoma | 5/42 12% | 21/612 3% |
| Acute Myeloid Leukemia | 3/90 3% | 0/0 0% |
| Melanoma | 7/210 3% | 42/1899 2% |
| Bladder Carcinoma | 0/58 0% | 23/956 2% |
| Hodgkins Lymphoma | 2/16 12% | 1/122 1% |
| Colorectal Carcinoma | 19/143 13% | 52/3239 2% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Cervical Carcinoma | 0/35 0% | 8/422 2% |
| Gastric Carcinoma | 0/74 0% | 28/1809 2% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 12/810 1% |
| Other Sarcomas | 3/69 4% | 6/699 1% |
| Other Solid Cancers | 2/94 2% | 16/1515 1% |
| Non-Small Cell Lung Carcinoma | 7/304 2% | 11/1390 1% |
| Ewings Sarcoma | 1/63 2% | 2/262 1% |
| Burkitts Lymphoma | 2/32 6% | 0/196 0% |
| Glioma | 0/52 0% | 19/2127 1% |
| Plasma Cell Myeloma | 2/44 5% | 1/305 0% |
| Hepatocellular Carcinoma | 0/46 0% | 17/2210 1% |
| Head and Neck Carcinoma | 4/85 5% | 8/1574 1% |
| Biliary Tract Carcinoma | 0/54 0% | 7/950 1% |
| Pancreatic Carcinoma | 2/89 2% | 9/1611 1% |
| Non-Cancerous | 0/104 0% | 5/830 1% |
| Esophageal Carcinoma | 0/23 0% | 4/769 1% |
| Kidney Carcinoma | 2/85 2% | 8/1862 0% |
| Neuroblastoma | 3/87 3% | 4/1331 0% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Breast Carcinoma | 5/144 3% | 11/3264 0% |
Mutation Distribution
Where IPO5 is mutated · all tissues, split by cell line vs tissue
How many mutations in IPO5 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 890 mutations in IPO5
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|